Pharma: Page 52
-
Merck, Bayer win FDA approval for heart failure drug
The drugmakers could face an uphill battle, however, to market the medicine, which showed a more modest benefit than expected in a key study.
By Kristin Jensen • Jan. 20, 2021 -
Kendall Davis/Industry Dive/BioPharma Dive, data from Marc Nozell
Former FDA chief Kessler tapped as top Biden adviser for COVID-19 response
David Kessler, who served in both the first Bush and Clinton administrations, will be joined by former acting Medicare head Andy Slavitt in a revamped effort from the new administration.
By Jonathan Gardner • Jan. 15, 2021 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Permission granted by PQE Group
Sponsored by PQE GroupPQE Group creates an internal research task force to fight the spread of misinformation in relation to COVID-19
PQE Group creates internal task force to fight the biggest side effect of the Covid-19 pandemic: the infodemic. A common vocabulary to reinforce knowledge, security and safety.
Jan. 11, 2021 -
Permission granted by Roche
Roche adds to RNA drug deal streak with Ribometrix partnership
The companies' pact is the latest addition to a growing list of deals involving startups developing chemical drugs to target RNA molecules.
By Ben Fidler • Jan. 6, 2021 -
AbbVie, Biogen lead pharma in new year's drug price hikes
Average list price increases across the drug industry, however, appear lower than last year, according to one analysis.
By Jonathan Gardner • Jan. 4, 2021 -
Permission granted by Bristol-Myers Squibb
How an all-or-nothing bet on 3 Bristol Myers drugs came undone
With no decision from the FDA on approval of an experimental cancer cell therapy, an agreement by Bristol Myers to pay out more money as part of its Celgene acquisition fell apart.
By Ned Pagliarulo • Jan. 4, 2021 -
skynesher via Getty Images
Sponsored by SGSSurface plasmon resonance in biopharmaceutical industry: Real-time and label-free characterization
Surface Plasmon Resonance (SPR) is a robust, but complex analytical tool that provides paramount value to the development and understanding biopharmaceutical products.
By Dr. Sasmit S. Deshmukh and Dr. Alex Perieteanu • Jan. 4, 2021 -
Courtesy of AstraZeneca
UK authorizes AstraZeneca, Oxford coronavirus vaccine, but questions linger
The first public vaccinations with AstraZeneca and Oxford’s shot are now underway. But it’s still unclear how effective the vaccine is, or the best way to use it.
By Ben Fidler • Dec. 30, 2020 -
Merck signs $356M deal to supply US with experimental coronavirus drug
The drugmaker spent $425 million a month ago to acquire the biotech developer of the treatment, which tamps down on the body's inflammatory response to viral infections.
By Jonathan Gardner • Dec. 23, 2020 -
Courtesy of BioNTech
US pays another $2B to buy more doses of Pfizer, BioNTech coronavirus vaccine
The new deal will provide the U.S. with 100 million additional doses of Pfizer and BioNTech's shot, but the much-needed supply won't be available for several months.
By Ben Fidler • Dec. 23, 2020 -
Permission granted by University of Maryland School of Medicine
Rollout of Pfizer's coronavirus vaccine hits some speed bumps amid confusion over shipments
Several thousand doses were returned and replaced after getting too cold. Pfizer and the federal government, meanwhile, don't appear to be on the same page for the next wave of shipments.
By Matt Leonard • Dec. 18, 2020 -
Novartis acquires a small biotech and its trio of brain drugs
More active in neuroscience than most pharmaceutical firms, Novartis would gain three experimental drugs for depression, schizophrenia and movement disorders through the deal.
By Jacob Bell • Dec. 17, 2020 -
With trial plans, Novo wagers its diabetes drug can help treat Alzheimer's
Similar diabetes drugs from Novo have shown signs of promise in treating dementia. The Danish biotech is now putting that hypothesis to the test.
By Jonathan Gardner • Dec. 16, 2020 -
Courtesy of BioNTech
In historic decision, FDA clears coronavirus vaccine from Pfizer, BioNTech
The vaccine was the first authorized for emergency use in the U.S. after a large study showed it to be highly protective against COVID-19, a landmark moment amid a worsening pandemic.
By Jonathan Gardner • Dec. 11, 2020 -
Viatris to lay off staff, shutter plants in major restructuring
The company created by a merger of Mylan and Pfizer's Upjohn unit is dramatically cutting costs, shedding jobs and closing or divesting up to 15 plants worldwide.
By Ned Pagliarulo • Dec. 11, 2020 -
Sanofi, GSK coronavirus vaccine delayed after early study disappoints
The experimental shot produced a weak immune response in adults over 49, leading the partner drugmakers to change plans and push back their development timelines.
By Ben Fidler • Dec. 11, 2020 -
Boehringer goes after antibody cancer drugs in latest acquisition
For about $1.4 billion, Boehringer will take control of NBE-Therapeutics and its antibody drug conjugate technology, which has already produced one clinical-stage therapy.
By Kristin Jensen • Dec. 10, 2020 -
Jonathan Gardner/BioPharma Dive
Lilly to pit Loxo cancer drug against top-selling rival after strong study results
Following positive data at ASH, Lilly will test a drug it acquired in last year's buyout of Loxo Oncology against Imbruvica, one of the world's best-selling cancer treatments.
By Ned Pagliarulo • Dec. 7, 2020 -
Sponsored by SAP
Solving supply chain volatility
Supply chain management technologies help monitor shifting demand patterns and ensure life-saving medications reach people quickly and at manageable costs.
By Mandar Paralkar, Global Head of Life Sciences at SAP • Dec. 7, 2020 -
J&J study finds multiple myeloma cell therapy to be strongly effective
Safety issues that have dogged the CAR-T field remain, however, with the drugmaker reporting some severe side effects, including several that led to patient deaths.
By Jonathan Gardner • Dec. 5, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
Lilly, UnitedHealth explore how to best use a COVID-19 antibody drug
A new real-world study will focus on in-home testing and administration of Lilly's bamlanivimab, which was recently cleared for emergency use in certain patients infected with the coronavirus.
By Jacob Bell • Dec. 4, 2020 -
Courtesy of Eli Lilly
US buys another 650,000 doses of Lilly's COVID-19 drug as outbreak surges
The U.S. government has ramped up spending on Lilly's and Regeneron's antibody-based COVID-19 treatments, but each remain in short supply.
By Kristin Jensen • Dec. 3, 2020 -
Permission granted by University of Maryland School of Medicine
UK drug regulator is first to clear Pfizer, BioNTech's coronavirus vaccine
The approval is a notable milestone in the historic pursuit of a protective shot for COVID-19. The two drugmakers plan to ship the first doses within days.
By Jonathan Gardner • Dec. 2, 2020 -
FAA says first flight shipping coronavirus vaccine takes off
With two experimental shots now undergoing FDA review, airports and shipping companies are readying for the mass shipment of vaccine doses.
By Matt Leonard • Nov. 30, 2020 -
A closer look at the behind-the-scenes companies moving coronavirus vaccines around the world
Freight forwarders, the linchpins of the supply chain, face the daunting task of ensuring hundreds of millions of doses make the journey from factory to clinic.
By Deborah Abrams Kaplan • Nov. 30, 2020
Previous
